Crovari P, Caffarena G, Coppola R, Di Pietro P, Gasparini R, Gelli G P, Icardi G C, Pantarotto M F
Boll Ist Sieroter Milan. 1984 Sep;63(4):290-8.
Thirty neonates to HBsAg carrier mothers, two of whom were HBeAg positive, received passive-active immunoprophylaxis. Within 48 hours after birth and at the first month of life these newborns were given HBIG (0.5 ml/Kg) and at the third month of life they were given first vaccination (10 micrograms). "HB-Vax" (M.S.D.) has been employed and its schedule has been performed (2 degrees and 3 degrees injections respectively at 4th and 9th month of life). Blood specimens have been collected in infants at birth and at each HBIG and vaccine administration, two months after the 2nd vaccination, one and six months after the third one. All specimens have been tested for HBV markers: HBsAg, anti-HBs, anti-HBc, anti-HBe and anti-HBc IgM. The anti-HBs titration has been performed according to WHO International Reference anti-HBs Standard. ALT and AST levels were determined in all infants specimens. The newborns did not show clinical signs or lab tests expressing HBV infection during the follow-up period. The anti-HBs geometric mean titres have been the following: 125 mIU/ml at 1 month, 176.4 mIU/ml at 3 months, 64.4 mIU/ml at 4 months, 119 mIU/ml at 6 months, 321 mIU/ml at 9 months, 2580.8 mIU/ml at 10 months and 715.3 mIU/ml at 15 months of life. Finally, side effects were observed for no infants.
30名母亲为乙肝表面抗原携带者的新生儿接受了被动-主动免疫预防,其中两名母亲乙肝e抗原呈阳性。这些新生儿在出生后48小时内及出生后第一个月接受了乙肝免疫球蛋白(0.5毫升/千克),在出生后第三个月接受了首次疫苗接种(10微克)。使用了“HB-Vax”(默克公司生产)并按照其接种程序进行接种(分别在出生后第4个月和第9个月进行第二剂和第三剂注射)。在婴儿出生时、每次接种乙肝免疫球蛋白和疫苗时、第二次接种后两个月、第三次接种后1个月和6个月采集血样。所有血样均检测了乙肝病毒标志物:乙肝表面抗原、乙肝表面抗体、乙肝核心抗体、乙肝e抗体和乙肝核心抗体IgM。按照世界卫生组织国际乙肝表面抗体标准进行乙肝表面抗体滴度测定。测定了所有婴儿血样中的谷丙转氨酶和谷草转氨酶水平。在随访期间,这些新生儿未出现表明乙肝病毒感染的临床症状或实验室检查结果。乙肝表面抗体几何平均滴度如下:1个月时为125毫国际单位/毫升,3个月时为176.4毫国际单位/毫升,4个月时为64.4毫国际单位/毫升,6个月时为119毫国际单位/毫升,9个月时为321毫国际单位/毫升,10个月时为2580.8毫国际单位/毫升,15个月时为715.3毫国际单位/毫升。最后,未观察到任何婴儿出现副作用。